<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gan Y</submitter><funding>National Natural Science Foundation of China</funding><funding>Outstanding Professorship Program of Chongqing Medical University</funding><pagination>e10224</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12866795</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(6)</volume><pubmed_abstract>Tumor-related metabolites in the tumor microenvironment may induce immune dysfunction, leading to malignant progression and metastasis of tumors. Here, it is demonstrated that tumoral PLA2G16, a phospholipase catalyzes phospholipids to generate free fatty acid (FFA) or lysophosphatidic acid (LPA), is an important contributor to triple-negative breast cancer (TNBC) lung metastasis in an immune-dependent pattern by improving tetracosatetraenoic acid (C24:4 (n-6)) accumulation in the early metastatic niche of lung and impairing immune function of pulmonary CD8&lt;sup>+&lt;/sup> T cells. C24:4 (n-6) induces nuclear import of PPARα in pneumal CD8&lt;sup>+&lt;/sup> T cells, which regulates the transcription of Cpt1a, Dgat1, Cd36, and Fabp1, leading to the activation of fatty acid oxidation (FAO). The robust FAO results in suppression of CD8&lt;sup>+&lt;/sup> T cells. Genetically depleting PPARα in mice, pharmacologically inhibiting C24:4 (n-6)-induced PPARα in the nucleus or directly suppressing PPARα activity effectively attenuates PLA2G16-C24:4 (n-6) axis-based immune dysfunction of CD8&lt;sup>+&lt;/sup> T cells and their according anti-tumor activities. These results imply that PLA2G16-mediated C24:4 (n-6) accumulation in the lung acts as a metabolic disorder to CD8&lt;sup>+&lt;/sup> T cell antitumor activity and highlights a critical role of PLA2G16 in promoting TNBC lung metastasis. Targeting PLA2G16 and combination with anti-PD-1-based immunotherapy may be an effective strategy for clinical tumor immunotherapy.</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>PLA2G16-Mediated Tetracosatetraenoic Acid Rewires Fatty Acid Oxidation to Impair CD8&amp;lt;sup&amp;gt;+&amp;lt;/sup&amp;gt; T Cell Immune Function in Promoting Breast Cancer Lung Metastasis.</pubmed_title><pmcid>PMC12866795</pmcid><funding_grant_id>82273295</funding_grant_id><funding_grant_id>R10005</funding_grant_id><funding_grant_id>82372823</funding_grant_id><funding_grant_id>NSFC82173155</funding_grant_id><pubmed_authors>Lang L</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Liu M</pubmed_authors><pubmed_authors>Lu Z</pubmed_authors><pubmed_authors>Tan D</pubmed_authors><pubmed_authors>Hou Y</pubmed_authors><pubmed_authors>Meng D</pubmed_authors><pubmed_authors>Luo J</pubmed_authors><pubmed_authors>Wang R</pubmed_authors><pubmed_authors>Dai P</pubmed_authors><pubmed_authors>Gan Y</pubmed_authors><pubmed_authors>Chang C</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Tang X</pubmed_authors></additional><is_claimable>false</is_claimable><name>PLA2G16-Mediated Tetracosatetraenoic Acid Rewires Fatty Acid Oxidation to Impair CD8&amp;lt;sup&amp;gt;+&amp;lt;/sup&amp;gt; T Cell Immune Function in Promoting Breast Cancer Lung Metastasis.</name><description>Tumor-related metabolites in the tumor microenvironment may induce immune dysfunction, leading to malignant progression and metastasis of tumors. Here, it is demonstrated that tumoral PLA2G16, a phospholipase catalyzes phospholipids to generate free fatty acid (FFA) or lysophosphatidic acid (LPA), is an important contributor to triple-negative breast cancer (TNBC) lung metastasis in an immune-dependent pattern by improving tetracosatetraenoic acid (C24:4 (n-6)) accumulation in the early metastatic niche of lung and impairing immune function of pulmonary CD8&lt;sup>+&lt;/sup> T cells. C24:4 (n-6) induces nuclear import of PPARα in pneumal CD8&lt;sup>+&lt;/sup> T cells, which regulates the transcription of Cpt1a, Dgat1, Cd36, and Fabp1, leading to the activation of fatty acid oxidation (FAO). The robust FAO results in suppression of CD8&lt;sup>+&lt;/sup> T cells. Genetically depleting PPARα in mice, pharmacologically inhibiting C24:4 (n-6)-induced PPARα in the nucleus or directly suppressing PPARα activity effectively attenuates PLA2G16-C24:4 (n-6) axis-based immune dysfunction of CD8&lt;sup>+&lt;/sup> T cells and their according anti-tumor activities. These results imply that PLA2G16-mediated C24:4 (n-6) accumulation in the lung acts as a metabolic disorder to CD8&lt;sup>+&lt;/sup> T cell antitumor activity and highlights a critical role of PLA2G16 in promoting TNBC lung metastasis. Targeting PLA2G16 and combination with anti-PD-1-based immunotherapy may be an effective strategy for clinical tumor immunotherapy.</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-15T06:08:45.058Z</modification><creation>2026-06-30T03:21:38.546Z</creation></dates><accession>S-EPMC12866795</accession><cross_references><pubmed>41241920</pubmed><doi>10.1002/advs.202510224</doi></cross_references></HashMap>